HK Stock Market Move | INNOGEN-B(02591) soared more than 21% in the afternoon, as the company vigorously promotes the commercialization of Exupla's peptide .

INNOGEN-B(02591) soared over 21% in the afternoon, rising 12.76% as of press time, to 22.8 Hong Kong dollars, with a transaction volume of 463.137 million Hong Kong dollars. On the news front, Yinnuo Pharmaceuticals released its annual results, with operating income of 132 million yuan, a net loss of 341 million yuan, and a 95.41% increase in losses year-on-year. R&D spending doubled to 206 million yuan during the period, mainly due to the company's increased investment in the production process improvement and clinical trials of isupaglucose . Meanwhile, sales and distribution expenses also increased significantly, from 2.39 million yuan in 2024 to 177 million yuan in 2025, mainly due to the company's expansion of market promotion and sales teams to support the commercialization of isupaglucose . The announcement stated that 2026 will be the first full fiscal year for the Group after the listing approval of isupaglucose . Building on inclusion in the national medical insurance catalog, the Group will continue to promote hospital access, channel coverage, and academic promotion for T2D indications, focusing on key hospitals in core markets, deepening penetration into grassroots healthcare institutions to improve patient access to medications and support wider applications within hospitals. The Group will also continue to expand its in-house marketing and sales teams, and strengthen its presence in key hospitals in core cities to support commercial execution.